GPC vs XCUR: Which Is the Better Buy in 2026?

Same yardstick, side by side (as of August 2026). Valuation lined up like this is most meaningful for two names in the same corner of the market, which these are. Figures are approximate; verify before investing.

The metrics above tell you which is the marginally better business. The bigger risk for most people is not picking the slightly worse stock, it is over-concentrating. GPC and XCUR share themes, so owning both, or adding either to what you already hold, can quietly push a large share of your portfolio into one bet.

This is the part a generic comparison page cannot answer, because it depends on what you own. Connect your brokerage and Walnut shows your real, combined GPC and XCUR exposure, flags overlap with your existing positions, and tells you if adding one would tip you past a concentration you are comfortable with, read-only by default, with your login staying at your broker. Walnut is not an investment adviser.

Genuine Parts Company is a large global distributor of automotive and industrial replacement parts. Its best-known business is automotive, where it operates and supplies the NAPA Auto Parts network, distributing replacement parts to repair shops, dealers, fleets, and consumers across North America, Europe, and Australasia. Its industrial segment, operating largely under the Motion brand, distributes bearings, power transmission, hydraulic, automation, and other industrial components to manufacturers and maintenance operations. Genuine Parts makes money by buying parts from thousands of suppliers and distributing them efficiently through an extensive network of distribution centers and stores, earning a margin on the value of logistics, availability, and breadth of inventory. Founded in 1928 and headquartered in Atlanta, Georgia, the company benefits from steady aftermarket demand: vehicles and machinery require maintenance and repair regardless of the economic cycle. It is a long-standing dividend payer with one of the longest records of consecutive dividend increases among US companies, making it a classic income and defensive holding.

Full GPC guide

Exicure is a clinical-stage biotechnology company whose identity has shifted dramatically. It was originally known for spherical nucleic acid (SNA) technology, but after those programs wound down it acquired assets from GPCR Therapeutics in January 2025 and repositioned itself around hematologic diseases. Its lead candidate is GPC-100, also called burixafor, a highly selective small-molecule antagonist of CXCR4, a receptor that helps retain hematopoietic stem cells in the bone marrow. The idea is to mobilize those stem cells more effectively so they can be collected for autologous transplant, initially in patients with multiple myeloma, with potential extensions to acute myeloid leukemia and other transplant or cell-and-gene-therapy settings.

Full XCUR guide

Both fit overlapping themes, but they are not interchangeable. The useful comparison is which set of drivers and risks you want exposure to.

• GPC drivers: Resilient aftermarket demand; Distribution scale and breadth.
• XCUR drivers: GPC-100 (burixafor) clinical progress; Capital and going-concern risk.

A faster-growing, richer-valued name usually swings harder, so it suits a longer horizon and a higher tolerance for volatility; a steadier, more cash-generative business suits a more conservative or income-minded investor. The honest test is which set of risks you could hold through a drawdown: Genuine Parts operates in a competitive, low-margin distribution business where pricing pressure, freight and labor costs, and inflation can squeeze profitability. For XCUR, the dominant risk is that Exicure is a pre-revenue, micro-cap biotech that has repeatedly reinvented itself and now depends on a single lead program plus fresh capital to survive.

Growth-minded investors who believe the theme has years to run tend to accept the richer multiple for more upside; value-minded investors lean toward the cheaper forward earnings and steadier profile. Pick GPC if you believe its drivers more; XCUR if you believe its. Many investors hold both, but since they share themes, that is a concentrated bet, not diversification. Decide deliberately and check overlap. For the full detail, see the GPC and XCUR guides.

GPC. Genuine Parts is valued as a stable, defensive distributor and dividend aristocrat rather than a growth name. Investors weigh resilient aftermarket demand and a long dividend-growth record against modest growth, thin distribution margins, and longer-term questions about electric vehicles. The valuation reflects steady cash generation and the reliability of its income profile across economic cycles.

XCUR. Figures are qualitative and tied to the asOf date. Exicure is a rapidly changing micro-cap whose cash position, share count, and listing status can shift quickly with each raise or filing, so verify live numbers, going-concern language, and Nasdaq compliance status in the latest SEC filings and press releases before acting. Traditional earnings multiples are not meaningful here; the value is a bet on clinical success and on the company staying funded and listed.

Headline figures (approximate, early 2026): GPC shows revenue (ttm) ~$23 to 25 billion, operating margin ~mid to high single digits percent, net income (ttm) ~$1 billion or more, dividend yield ~2 to 3%; XCUR shows stage Clinical-stage: no approved product and minimal or no product revenue, lead asset GPC-100 (burixafor), a CXCR4 antagonist for stem-cell mobilization; positive Phase 2 topline data reported in multiple myeloma, financial condition Discloses need for additional capital; operating losses expected; verify latest cash runway in filings, listing status Received a Nasdaq minimum stockholders' equity deficiency notice in mid-2026 with a compliance window; confirm current status.

GPC and XCUR are related but distinct: same themes, different businesses and risks. Neither wins in the abstract; the right pick is whichever thesis you actually believe, sized so you are not over-concentrated in one theme. Walnut can show your combined GPC and XCUR exposure against your real portfolio. It is not an investment adviser.